Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NELIA ESTHER SANCHEZ-CRESPO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1790990851
CMS profile
699626
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$281.68

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $281.68 15

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NELIA ESTHER SANCHEZ-CRESPO

NPI 1790990851 · CMS profile ID 699626

Allopathic & Osteopathic Physicians / Internal Medicine

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790990851?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790990851?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790990851?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1790990851?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $281.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $16.5912/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894320157 CMS
Novo Nordisk Inc $22.2311/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899552965 CMS
Lilly USA, LLC $14.1110/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918248321 CMS
Lilly USA, LLC $14.5909/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918271689 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.9909/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930034575 CMS
Bayer HealthCare Pharmaceuticals Inc. $25.9408/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930113165 CMS
Abbott Laboratories $19.1407/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907947417 CMS
EISAI INC. $19.0907/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908070707 CMS
Bayer HealthCare Pharmaceuticals Inc. $27.2707/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930102521 CMS
EISAI INC. $20.4007/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908070711 CMS
Eisai Inc. $14.7305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935312267 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.3303/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930189431 CMS
EISAI INC. $16.3703/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908070703 CMS
Novartis Pharmaceuticals Corporation $16.5003/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894320161 CMS
Currax Pharmaceuticals LLC $16.4001/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925772099 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $519.24 8
PY2020 $173.44 11
PY2021 $252.44 16
PY2022 $281.68 15
PY2023 $2,585.02 22
PY2024 $2,063.21 35
PY2025 $728.73 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,652,523.02 227
PY2024 Principal investigator $7,882,760.60 649
PY2023 Principal investigator $10,990,435.50 4,306
PY2022 Principal investigator $2,420,977.88 1,673
PY2021 Principal investigator $723,239.31 8
PY2020 Principal investigator $1,155,430.22 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

4,306 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $642.35 12/31/2023 Non-covered Recipient Entity
Research Centers of America Hollywood
An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Molnupiravir MK-4482 in Participants with Moderate Hepatic Impairment No dispute reported 06/30/2026 1042525507
Principal investigator 1 PFIZER INC. $3,529.50 12/30/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1045987259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027863
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654797
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654809
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654821
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654833
Principal investigator 1 ModernaTX, Inc. $1,878.44 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654845
Principal investigator 1 ModernaTX, Inc. $410.02 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654857
Principal investigator 1 ModernaTX, Inc. $1,903.14 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654869
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654893
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654909
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654923
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654933
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654945
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654959
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654969
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654981
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041654993
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655003
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655011
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655029
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655039
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655051
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655065
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655073
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655087
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655099
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655111
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655123
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655135
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655147
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655159
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655173
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655185
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655197
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655209
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655219
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655231
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655243
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655255
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655267
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655279
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655291
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655303
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655315
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655329
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655341
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655353
Principal investigator 1 ModernaTX, Inc. $1,878.44 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655365
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655375
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655387
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655400
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655413
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655425
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655433
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655445
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655459
Principal investigator 1 ModernaTX, Inc. $1,878.44 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655471
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655483
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655497
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655507
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655519
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655533
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655541
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655553
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655569
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655579
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655593
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655603
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655613
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655627
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655639
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655651
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655663
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655673
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655685
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655697
Principal investigator 1 ModernaTX, Inc. $410.02 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655709
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041655991
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656003
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656015
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656023
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656033
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656047
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656059
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656071
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656083
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656095
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656105
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656117
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656131
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656143
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656155
Principal investigator 1 ModernaTX, Inc. $1,903.14 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656167
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656179
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656191
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656203
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656215
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656227
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656239
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656251
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656263
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656275
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656287
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656299
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656309
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656323
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656335
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656347
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656359
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656373
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656385
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656395
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656407
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656419
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656431
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656445
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656457
Principal investigator 1 ModernaTX, Inc. $1,878.44 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656467
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656481
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656493
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656505
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656517
Principal investigator 1 ModernaTX, Inc. $410.02 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656529
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656541
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656553
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656565
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656577
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656589
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656603
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656617
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656631
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656642
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656655
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656667
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656679
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656693
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656705
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656717
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656729
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656741
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656753
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656763
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656775
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656787
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656803
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656811
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656823
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656835
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656845
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656853
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656866
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656879
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656889
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656897
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656903
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656913
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656923
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656935
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656945
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656957
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656969
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656981
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041656991
Principal investigator 1 ModernaTX, Inc. $410.02 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657003
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657015
Principal investigator 1 ModernaTX, Inc. $410.02 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657025
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657037
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657048
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657057
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657071
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657083
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657095
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657105
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657119
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657131
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657143
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657157
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657857
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657867
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657881
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657893
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657905
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657915
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657925
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657939
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657953
Principal investigator 1 ModernaTX, Inc. $1,157.20 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657963
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657973
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657985
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041657997
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658009
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658021
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658033
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658045
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658057
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658069
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658081
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658093
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658102
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658117
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658131
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658141
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658155
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658169
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658181
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658193
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658205
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658217
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658229
Principal investigator 1 ModernaTX, Inc. $2,061.80 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658243
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658257
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658269
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658281
Principal investigator 1 ModernaTX, Inc. $1,878.44 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658293
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658303
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658319
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658329
Principal investigator 1 ModernaTX, Inc. $1,958.71 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658341
Principal investigator 1 ModernaTX, Inc. $377.91 12/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041658353
Principal investigator 1 PFIZER INC. $3,675.00 12/21/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1046001911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 12/20/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028583
Principal investigator 1 ModernaTX, Inc. $260.00 12/20/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041654879
Principal investigator 1 ModernaTX, Inc. $1,340.00 12/15/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220997
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653023
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653035
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653047
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653059
Principal investigator 1 ModernaTX, Inc. $1,830.60 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653071
Principal investigator 1 ModernaTX, Inc. $1,306.80 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653083
Principal investigator 1 ModernaTX, Inc. $1,337.85 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653093
Principal investigator 1 ModernaTX, Inc. $1,425.60 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653105
Principal investigator 1 ModernaTX, Inc. $2,012.85 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041653115
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041653127
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041653139
Principal investigator 1 ModernaTX, Inc. $649.17 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041653153
Principal investigator 1 ModernaTX, Inc. $377.91 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1041653167
Principal investigator 1 ModernaTX, Inc. $1,494.45 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653177
Principal investigator 1 ModernaTX, Inc. $1,275.75 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653211
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653225
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653237
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653247
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653259
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653269
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653281
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653293
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653305
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653317
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653329
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653341
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653353
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653365
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653377
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653389
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653399
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653413
Principal investigator 1 ModernaTX, Inc. $2,012.85 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041653426
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653587
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653599
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653611
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653623
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653635
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653649
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653661
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653673
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653687
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653699
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653711
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041653723
Principal investigator 1 ModernaTX, Inc. $1,830.60 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653731
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041653741
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653759
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653769
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653785
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653795
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653807
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653821
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653833
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653845
Principal investigator 1 ModernaTX, Inc. $2,012.85 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041653857
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653869
Principal investigator 1 ModernaTX, Inc. $649.17 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041653881
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653893
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653905
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041653915
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041653927
Principal investigator 1 ModernaTX, Inc. $2,012.85 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041653941
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653953
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653965
Principal investigator 1 ModernaTX, Inc. $1,306.80 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041653977
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041653989
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654001
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654015
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654027
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654039
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654053
Principal investigator 1 ModernaTX, Inc. $1,306.80 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654065
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654077
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654089
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654101
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654113
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654125
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654137
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654149
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654161
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654173
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041654185
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654197
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654209
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654221
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654233
Principal investigator 1 ModernaTX, Inc. $1,306.80 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654245
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654257
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654271
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654281
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654293
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041654305
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041654317
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654329
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654341
Principal investigator 1 ModernaTX, Inc. $2,012.85 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041654353
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654365
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654379
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041654389
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654403
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654413
Principal investigator 1 ModernaTX, Inc. $1,425.60 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654423
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654435
Principal investigator 1 ModernaTX, Inc. $649.17 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654447
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654459
Principal investigator 1 ModernaTX, Inc. $1,306.80 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654471
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654485
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654497
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654511
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654521
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654533
Principal investigator 1 ModernaTX, Inc. $1,240.65 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041654545
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654559
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654569
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654581
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654593
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654603
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654615
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654627
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654637
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654650
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654663
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654677
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654687
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041654699
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654713
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654725
Principal investigator 1 ModernaTX, Inc. $1,439.19 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041654737
Principal investigator 1 ModernaTX, Inc. $1,830.60 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654749
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654760
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041654771
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041654783
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655719
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041655731
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041655743
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655755
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655767
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655779
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655791
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041655803
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655815
Principal investigator 1 ModernaTX, Inc. $1,306.80 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655827
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655839
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655851
Principal investigator 1 ModernaTX, Inc. $672.03 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655859
Principal investigator 1 ModernaTX, Inc. $649.17 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041655873
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041655883
Principal investigator 1 ModernaTX, Inc. $541.59 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041655895
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655907
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655919
Principal investigator 1 ModernaTX, Inc. $496.13 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041655931
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655943
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655955
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655967
Principal investigator 1 ModernaTX, Inc. $155.25 12/14/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041655979
Principal investigator 1 SANOFI PASTEUR INC. $1,750.00 12/13/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879951
Principal investigator 1 PFIZER INC. $117.40 12/12/2023 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045927763
Principal investigator 1 PFIZER INC. $7.52 12/12/2023 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046054859
Principal investigator 1 BioNTech SE $357.20 12/08/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317705
Principal investigator 1 Novavax Inc $526.49 12/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055259621
Principal investigator 1 GlaxoSmithKline, LLC. $1,433.77 12/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1127787924
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 12/05/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035880015
Principal investigator 1 Mylan Technologies Inc. $59.79 12/04/2023 Non-covered Recipient Entity
CenExel Clinical Research Inc
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety No dispute reported 06/30/2026 1038024271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,824.80 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,842.15 12/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028565
Principal investigator 1 ModernaTX, Inc. $1,340.00 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041653189
Principal investigator 1 ModernaTX, Inc. $8,650.00 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041653199
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653435
Principal investigator 1 ModernaTX, Inc. $14.36 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653449
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653461
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653473
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653485
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653497
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653509
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653519
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653531
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653543
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653555
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653567
Principal investigator 1 ModernaTX, Inc. $154.14 12/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041653577
Principal investigator 1 SANOFI PASTEUR INC. $18,720.72 12/01/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027695
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041650883
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041650889
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041650897
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650905
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650913
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650921
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650929
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650936
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650943
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650953
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650959
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650967
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650975
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650985
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650993
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651001
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651009
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651017
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651025
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651033
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651043
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651051
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651059
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651069
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651079
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651087
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651095
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651103
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651111
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651119
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651127
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651135
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651143
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651151
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651161
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651169
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651179
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651187
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651195
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651203
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651213
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651219
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651227
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651237
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651245
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651255
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651263
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651271
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651279
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651287
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651293
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651307
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651315
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651321
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651329
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651336
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651345
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651353
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651359
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651369
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651375
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651385
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651393
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651401
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651409
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651417
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651425
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651433
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651441
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651449
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651457
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651465
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651473
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651481
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651489
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651497
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651505
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651513
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651523
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651531
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651539
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651547
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651557
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651565
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651573
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651583
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651593
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651605
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651617
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651629
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651641
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651655
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651667
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651679
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651691
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651701
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651713
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651725
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651739
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651751
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651761
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651775
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651787
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651799
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651811
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041651825
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651837
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651849
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651861
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651873
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041651885
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651897
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651909
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651921
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651933
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651945
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651957
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651969
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651981
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041651993
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652005
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652017
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652029
Principal investigator 1 ModernaTX, Inc. $646.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652041
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652055
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652067
Principal investigator 1 ModernaTX, Inc. $649.17 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041652079
Principal investigator 1 ModernaTX, Inc. $672.03 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041652090
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652101
Principal investigator 1 ModernaTX, Inc. $1,240.65 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041652113
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652125
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652139
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652151
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652161
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652173
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652187
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652199
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652211
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652223
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652237
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652249
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652259
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652271
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652285
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652297
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652307
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652319
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652331
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652343
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652357
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652371
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652383
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652395
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652407
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652419
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652433
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652445
Principal investigator 1 ModernaTX, Inc. $2,390.42 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652455
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652467
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652479
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652495
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652507
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652519
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652531
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652551
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652563
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652575
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652587
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652597
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652611
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652625
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652634
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652645
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652659
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652669
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652681
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652693
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652705
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652717
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652729
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652741
Principal investigator 1 ModernaTX, Inc. $2,390.42 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652753
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652765
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652777
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652789
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652801
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652813
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652825
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652841
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652853
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652867
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652877
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652889
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652901
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652915
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652927
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652939
Principal investigator 1 ModernaTX, Inc. $541.59 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652951
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652961
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652975
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652987
Principal investigator 1 ModernaTX, Inc. $1,840.29 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041652999
Principal investigator 1 ModernaTX, Inc. $1,605.39 11/28/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041653011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $910.60 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,816.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/27/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028417
Principal investigator 1 PFIZER INC. $403.92 11/27/2023 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046008943
Principal investigator 1 PFIZER INC. $3,014.40 11/25/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1045952785
Principal investigator 1 PFIZER INC. $6,070.12 11/25/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046031585
Principal investigator 1 ModernaTX, Inc. $375.00 11/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220863
Principal investigator 1 ModernaTX, Inc. $3,044.13 11/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220865
Principal investigator 1 ModernaTX, Inc. $1,340.00 11/17/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041629297
Principal investigator 1 ModernaTX, Inc. $1,750.00 11/16/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041651301
Principal investigator 1 SANOFI PASTEUR INC. $780.14 11/10/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879975
Principal investigator 1 Novavax Inc $4,211.92 11/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055265533
Principal investigator 1 PFIZER INC. $1,527.00 11/09/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046090647
Principal investigator 1 Mylan Technologies Inc. $19,100.00 11/06/2023 Non-covered Recipient Entity
CenExel Clinical Research Inc
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety No dispute reported 06/30/2026 1038024277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,027.15 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,227.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,583.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,583.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,583.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,583.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,583.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,376.00 11/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028381
Principal investigator 1 PFIZER INC. $1,179.35 11/03/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1046001229
Principal investigator 1 PFIZER INC. $3,035.06 11/03/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046072891
Principal investigator 1 ModernaTX, Inc. $1,340.00 11/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041629287
Principal investigator 1 Alnylam Pharmaceuticals Inc. $866.55 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,816.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,816.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,816.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 11/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028241
Principal investigator 1 GlaxoSmithKline, LLC. $8,432.26 11/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1006255043
Principal investigator 1 GlaxoSmithKline, LLC. $1,806.91 11/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1006255049
Principal investigator 1 ModernaTX, Inc. $11,567.70 11/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220859
Principal investigator 1 ModernaTX, Inc. $2,160.00 11/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027517
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650489
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650498
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650507
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650515
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650521
Principal investigator 1 ModernaTX, Inc. $1,063.19 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650529
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650537
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650545
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650555
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650561
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650645
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650761
Principal investigator 1 ModernaTX, Inc. $672.03 10/30/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041650819
Principal investigator 1 SANOFI PASTEUR INC. $1,750.00 10/30/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879989
Principal investigator 1 SANOFI PASTEUR INC. $1,920.00 10/30/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035880003
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645585
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645595
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645605
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645617
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645627
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645637
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645649
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645663
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645673
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645683
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645693
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645703
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645713
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645723
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645733
Principal investigator 1 ModernaTX, Inc. $646.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645743
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645753
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645763
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645773
Principal investigator 1 ModernaTX, Inc. $303.75 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645781
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645793
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645803
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645813
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645825
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645833
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645843
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645853
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645863
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645873
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645883
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645893
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645903
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645915
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645925
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645935
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645945
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645957
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645967
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645977
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645987
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041645997
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646007
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646017
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646027
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646037
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646047
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646055
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646065
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646077
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646087
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646097
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646107
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646117
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646127
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646137
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646147
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646601
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646611
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646621
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646629
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646639
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646649
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646659
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646669
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646681
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646691
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646701
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646709
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646719
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646733
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646739
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646747
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646757
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646767
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646775
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646785
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646795
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646805
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646816
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646825
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646835
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646845
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646855
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646866
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646877
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646887
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646897
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646905
Principal investigator 1 ModernaTX, Inc. $646.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646916
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646929
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646939
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646949
Principal investigator 1 ModernaTX, Inc. $646.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646959
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646969
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646981
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041646991
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647001
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647011
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647021
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647033
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647043
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647051
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647063
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647071
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647083
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647093
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647103
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647115
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647125
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647135
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647145
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647155
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647165
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647173
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647183
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647197
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647211
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647219
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647229
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647239
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647251
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647259
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647269
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647281
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647291
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647301
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647311
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647323
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647333
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647343
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647353
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647363
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647373
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647385
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647395
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647403
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647413
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647425
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647435
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647445
Principal investigator 1 ModernaTX, Inc. $646.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647455
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647465
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647475
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647485
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647495
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647505
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647517
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647527
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647537
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647547
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647557
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647565
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647575
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647585
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647595
Principal investigator 1 ModernaTX, Inc. $646.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647607
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647617
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647625
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647635
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647647
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647656
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647667
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647675
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647687
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647699
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647709
Principal investigator 1 ModernaTX, Inc. $646.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647717
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647727
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647737
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647747
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647761
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647771
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647781
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647791
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647801
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647811
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647821
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647831
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647841
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647851
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647861
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647871
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647883
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647893
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647903
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647913
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647923
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647933
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647943
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647953
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647961
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647971
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647981
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041647991
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648001
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648011
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648021
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648031
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648043
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648053
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648063
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648071
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648081
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648093
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648103
Principal investigator 1 ModernaTX, Inc. $303.75 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648113
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648123
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648131
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648143
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648153
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648165
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648173
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648183
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648193
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648203
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648213
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648223
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648233
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648243
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648253
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648263
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648273
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648283
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648293
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648303
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648313
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648323
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648333
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648343
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648353
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648363
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648373
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648381
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648391
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648401
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648413
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648423
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648433
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648445
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648453
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648465
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648475
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648483
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648493
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648503
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648515
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648524
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648533
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648543
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648553
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648563
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648573
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648583
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648597
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648607
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648617
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648627
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648637
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648647
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648659
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648669
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648679
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648689
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648699
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648709
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648719
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648729
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648739
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648749
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648759
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648769
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648779
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648791
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648799
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648809
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648821
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648831
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648839
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648849
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648859
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648869
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648879
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648893
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648903
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648913
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648923
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648933
Principal investigator 1 ModernaTX, Inc. $303.75 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648944
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648953
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648961
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648973
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648981
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041648995
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649005
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649015
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649025
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649035
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649045
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649053
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649063
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649073
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649083
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649093
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649105
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649113
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649121
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649131
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649143
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649153
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649163
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649173
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649183
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649193
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649203
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649211
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649223
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649235
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649245
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649255
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649265
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649275
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649285
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649295
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649305
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649320
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649331
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649341
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649349
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649361
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649371
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649381
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649391
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649401
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649411
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649419
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649430
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649441
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649451
Principal investigator 1 ModernaTX, Inc. $303.75 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649459
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649469
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649479
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649491
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649499
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649509
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649519
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649529
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649539
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649549
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649559
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649567
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649577
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649587
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649597
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649607
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649617
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649627
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649637
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649647
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649657
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649667
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649677
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649687
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649695
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649705
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649717
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649727
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649737
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649747
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649756
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649767
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649777
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649787
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649797
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649807
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649817
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649827
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649837
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649847
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649857
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649863
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649869
Principal investigator 1 ModernaTX, Inc. $303.75 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649875
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649883
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649891
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649899
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649909
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649915
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649923
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649933
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649939
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649951
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649956
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649966
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649973
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649983
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041649991
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650001
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650009
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650017
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650025
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650033
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650041
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650050
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650059
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650067
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650075
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650083
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650091
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650099
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650107
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650115
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650121
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650131
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650138
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650145
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650157
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650163
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650171
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650179
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650187
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650195
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650203
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650213
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650221
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650229
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650237
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650245
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650253
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650261
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650269
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650277
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650285
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650293
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650301
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650309
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650317
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650325
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650335
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650343
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650351
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650359
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650367
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650377
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650385
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650393
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650401
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650409
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650417
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650425
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650433
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650441
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650451
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650459
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650467
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650475
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650481
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650569
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650577
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650587
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650595
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650603
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650611
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650621
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650629
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650637
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650653
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650661
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650669
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650677
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650685
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650697
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650703
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650711
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650719
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650727
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650735
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650743
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650753
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650769
Principal investigator 1 ModernaTX, Inc. $2,111.40 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650777
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650785
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650795
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650801
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650810
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650827
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650835
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650843
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650851
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650859
Principal investigator 1 ModernaTX, Inc. $727.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650867
Principal investigator 1 ModernaTX, Inc. $1,159.65 10/27/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041650875
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640495
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640505
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041640535
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640545
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640557
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640567
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640577
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640588
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640601
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640621
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640631
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640641
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640651
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640663
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640673
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640683
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640713
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640723
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640763
Principal investigator 1 ModernaTX, Inc. $2,335.50 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041640773
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641517
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641527
Principal investigator 1 ModernaTX, Inc. $2,523.63 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041641537
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041641547
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641557
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641567
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641577
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041641587
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641597
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641607
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641617
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641629
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641637
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641647
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641657
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641667
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641681
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641691
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641697
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641707
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641715
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041641725
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641735
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641743
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641753
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641761
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641771
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641779
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641791
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641803
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641813
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641823
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641833
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641843
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641853
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641863
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641875
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641885
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641895
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641909
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641919
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641929
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641941
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641951
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641961
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641969
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041641981
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641991
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642001
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642013
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642021
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642029
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642043
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642053
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642065
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642075
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642085
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642095
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642105
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642115
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642125
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642135
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642145
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642155
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642165
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642175
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642185
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642195
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642207
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642219
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642229
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642239
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642249
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642257
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642265
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642275
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642285
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642295
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642305
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642315
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642327
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642339
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642349
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642359
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642371
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642381
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642391
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642401
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642411
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642421
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642431
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642441
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642451
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642463
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642473
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642483
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642493
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642503
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642513
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642521
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642533
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642545
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642555
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642565
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642575
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642585
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642595
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642607
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642617
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642627
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642637
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642647
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642657
Principal investigator 1 ModernaTX, Inc. $1,422.90 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642667
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642677
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642687
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041642697
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642707
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642717
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642727
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642739
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642749
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642759
Principal investigator 1 ModernaTX, Inc. $646.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041642769
Principal investigator 1 ModernaTX, Inc. $649.17 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041642779
Principal investigator 1 ModernaTX, Inc. $496.13 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642789
Principal investigator 1 ModernaTX, Inc. $1,306.80 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041642799
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642809
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642819
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642827
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642837
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642847
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642857
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642867
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642877
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642887
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642897
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642907
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642915
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642927
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642935
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642946
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642957
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642965
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642975
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642985
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041642995
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643005
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643015
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643025
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643033
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643043
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643053
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643065
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643075
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643085
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643097
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643107
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643117
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643127
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643137
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643147
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643157
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643167
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643177
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643187
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643197
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643207
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643217
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643227
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643237
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643247
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643255
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643265
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643277
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643287
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643297
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643307
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643317
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643327
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643337
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643347
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643357
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643367
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643375
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643385
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643395
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643405
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643415
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643425
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643435
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643445
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643459
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643469
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643479
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643489
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643499
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643509
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643521
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643531
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643537
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643547
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643557
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643567
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643579
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643587
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643599
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643611
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643621
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643631
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643641
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643651
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643661
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643673
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643683
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643691
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643699
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643711
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643719
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643729
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643739
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643749
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643759
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643769
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643779
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643789
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643799
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643809
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643819
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643827
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643839
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643849
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643859
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643873
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643887
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643897
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643907
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643917
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643927
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643937
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643947
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643957
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643967
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643977
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643987
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041643997
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644009
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644019
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644029
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644039
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644047
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644057
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644067
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644077
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644087
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644097
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644107
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644117
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644127
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644137
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644147
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644159
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644169
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644179
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644189
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644199
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644209
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644219
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644231
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644241
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644251
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644261
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644271
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644281
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644291
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644301
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644311
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644321
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644331
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644345
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644353
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644365
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644373
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644383
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644393
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644403
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644415
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644423
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644433
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644443
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644455
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644463
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644473
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644483
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644493
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644503
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644513
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644527
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644533
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644543
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644553
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644563
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644575
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644585
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644595
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644605
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644615
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644625
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644637
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644647
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644657
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644665
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644679
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644689
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644699
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644709
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644719
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644727
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644737
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644747
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644759
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644767
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644779
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644787
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644797
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644811
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644821
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644831
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644841
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644853
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644865
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644875
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644883
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644893
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644905
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644915
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644923
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644935
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644943
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644955
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644965
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644975
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644985
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041644995
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645007
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645015
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645025
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645039
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645049
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645059
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645069
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645079
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645089
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645101
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645111
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645121
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645131
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645141
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645153
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645163
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645173
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645183
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645193
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645205
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645215
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645225
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645235
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645243
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645253
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645265
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645275
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645287
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645297
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645309
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645321
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645331
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645341
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645351
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645361
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645371
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645379
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645389
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645399
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645411
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645421
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645431
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645441
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645451
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645461
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645471
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645481
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645491
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645501
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645511
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645521
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645531
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645543
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645553
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645565
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041645575
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646157
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646167
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646177
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646187
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646197
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646207
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646217
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646225
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646233
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646243
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646255
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646265
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646273
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646285
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646295
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646305
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646315
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646325
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646333
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646343
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646353
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646365
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646375
Principal investigator 1 ModernaTX, Inc. $1,605.39 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646385
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646395
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646405
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646415
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646427
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646435
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646447
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646457
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646467
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646477
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646487
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646497
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646507
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646517
Principal investigator 1 ModernaTX, Inc. $2,995.65 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646527
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646541
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646551
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646561
Principal investigator 1 ModernaTX, Inc. $2,772.47 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646571
Principal investigator 1 ModernaTX, Inc. $1,840.29 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646581
Principal investigator 1 ModernaTX, Inc. $2,390.42 10/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041646591
Principal investigator 1 PFIZER INC. $825.00 10/25/2023 Non-covered Recipient Entity
Research Centers of America LLC
A 2 WEEK METHODOLOGY STUDY TO EVALUATE MUSCLE BIOMARKER PERFORMANCE AND MUSCLE BIOPSY PROCEDURE IN HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1045948635
Principal investigator 1 ModernaTX, Inc. $67.50 10/24/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041629267
Principal investigator 1 PFIZER INC. $15,880.20 10/24/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1045896925
Principal investigator 1 ModernaTX, Inc. $189.26 10/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041629277
Principal investigator 1 GlaxoSmithKline, LLC. $1,204.60 10/20/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1006255054
Principal investigator 1 SANOFI PASTEUR INC. $7,500.00 10/20/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879963
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640515
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640611
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640693
Principal investigator 1 ModernaTX, Inc. $2,312.55 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640703
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640733
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640743
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640753
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640783
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640793
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640801
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640811
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640821
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640831
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640841
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640851
Principal investigator 1 ModernaTX, Inc. $2,227.50 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640945
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640955
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641181
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641211
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641251
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641313
Principal investigator 1 ModernaTX, Inc. $2,695.95 10/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641437
Principal investigator 1 PFIZER INC. $23,745.51 10/12/2023 Non-covered Recipient Entity
Research Centers of America LLC
A 2 WEEK METHODOLOGY STUDY TO EVALUATE MUSCLE BIOMARKER PERFORMANCE AND MUSCLE BIOPSY PROCEDURE IN HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1046153673
Principal investigator 1 PFIZER INC. $7,479.92 10/12/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046191809
Principal investigator 1 ModernaTX, Inc. $2,523.63 10/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041640525
Principal investigator 1 PFIZER INC. $350.00 10/11/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045940371
Principal investigator 1 SANOFI PASTEUR INC. $6,800.00 10/11/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879889
Principal investigator 1 BioNTech SE $1,136.20 10/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317707
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639479
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639489
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639501
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639509
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041639519
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041639529
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041639539
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041639549
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041639561
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639571
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639581
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639593
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639603
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639611
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639621
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639631
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639641
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639651
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639661
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639671
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639681
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639691
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639701
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639713
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639723
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639733
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041639743
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041639753
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639763
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639773
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639783
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639793
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041639803
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639813
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639823
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639833
Principal investigator 1 ModernaTX, Inc. $202.50 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041639843
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639853
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639863
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639875
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041639885
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639895
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639905
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639915
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639925
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639937
Principal investigator 1 ModernaTX, Inc. $1,439.19 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041639947
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639957
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639969
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639979
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639989
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640001
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640009
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640019
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640029
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640041
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041640053
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640063
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640073
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640083
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640093
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640104
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640115
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041640125
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640135
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640145
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640155
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640163
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640173
Principal investigator 1 ModernaTX, Inc. $1,439.19 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041640183
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640193
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640203
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640213
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640223
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640233
Principal investigator 1 ModernaTX, Inc. $1,063.19 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640243
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640253
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640263
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640273
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640285
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041640293
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640305
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640315
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640323
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640333
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640343
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640353
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640363
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640373
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640383
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640395
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640405
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640415
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640425
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640435
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640445
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640455
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640463
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640861
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640871
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640881
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640893
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640905
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640913
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640923
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041640935
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640965
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640977
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640987
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041640997
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641007
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641015
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641025
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641035
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641045
Principal investigator 1 ModernaTX, Inc. $76.95 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641055
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641065
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641075
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641087
Principal investigator 1 ModernaTX, Inc. $577.76 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641097
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641107
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641117
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641129
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641137
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641147
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641159
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641171
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641189
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641201
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641221
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641231
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641241
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641261
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641271
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641281
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641292
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641301
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641325
Principal investigator 1 ModernaTX, Inc. $202.50 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641335
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641345
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641355
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641365
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641375
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641387
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641397
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641407
Principal investigator 1 ModernaTX, Inc. $1,439.19 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641417
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641425
Principal investigator 1 ModernaTX, Inc. $646.65 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041641447
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641457
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641467
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641477
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641487
Principal investigator 1 ModernaTX, Inc. $672.03 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041641497
Principal investigator 1 ModernaTX, Inc. $649.17 10/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041641507
Principal investigator 1 SANOFI PASTEUR INC. $23,613.57 10/06/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879903
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638635
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638735
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638891
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041639011
Principal investigator 1 ModernaTX, Inc. $1,742.04 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041639055
Principal investigator 1 ModernaTX, Inc. $2,012.85 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041639367
Principal investigator 1 ModernaTX, Inc. $1,742.04 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041640473
Principal investigator 1 ModernaTX, Inc. $1,742.04 10/05/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041640485
Principal investigator 1 ModernaTX, Inc. $8,650.00 10/04/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041629257
Principal investigator 1 BioNTech SE $86,058.00 10/03/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060313253
Principal investigator 1 BioNTech SE $24,594.55 10/03/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317699
Principal investigator 1 BioNTech SE $1,920.90 10/03/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317701
Principal investigator 1 BioNTech SE $7,112.65 10/03/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317703
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638645
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638655
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638664
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638673
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638685
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638693
Principal investigator 1 ModernaTX, Inc. $5,062.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638705
Principal investigator 1 ModernaTX, Inc. $4,050.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638715
Principal investigator 1 ModernaTX, Inc. $5,062.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638725
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638745
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638755
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638765
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638775
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638785
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638795
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638805
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638815
Principal investigator 1 ModernaTX, Inc. $5,062.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638827
Principal investigator 1 ModernaTX, Inc. $5,062.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638837
Principal investigator 1 ModernaTX, Inc. $3,037.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638847
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638859
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638869
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638881
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638901
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638909
Principal investigator 1 ModernaTX, Inc. $2,025.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638921
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638931
Principal investigator 1 ModernaTX, Inc. $5,062.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638941
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638951
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638961
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638971
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638983
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638991
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639001
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639021
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639031
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639041
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639065
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639075
Principal investigator 1 ModernaTX, Inc. $1,600.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041639085
Principal investigator 1 ModernaTX, Inc. $3,037.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639095
Principal investigator 1 ModernaTX, Inc. $6,075.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639105
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639115
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639125
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639133
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639145
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639153
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639165
Principal investigator 1 ModernaTX, Inc. $5,062.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639175
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639185
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639195
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639205
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639215
Principal investigator 1 ModernaTX, Inc. $2,025.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639225
Principal investigator 1 ModernaTX, Inc. $6,075.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639235
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639245
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639255
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639265
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639275
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639285
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639295
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639305
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639315
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639327
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639337
Principal investigator 1 ModernaTX, Inc. $4,050.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639345
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639357
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639377
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639387
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639397
Principal investigator 1 ModernaTX, Inc. $1,012.50 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041639407
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041639419
Principal investigator 1 ModernaTX, Inc. $500.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041639429
Principal investigator 1 ModernaTX, Inc. $9,000.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041639439
Principal investigator 1 ModernaTX, Inc. $10,000.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041639449
Principal investigator 1 ModernaTX, Inc. $896.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041639459
Principal investigator 1 ModernaTX, Inc. $1,250.00 10/02/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1041639469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140885
Principal investigator 1 ModernaTX, Inc. $33.75 09/29/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1042219163
Principal investigator 1 SANOFI PASTEUR INC. $109,204.20 09/29/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879537
Principal investigator 1 SANOFI PASTEUR INC. $850.50 09/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879655
Principal investigator 1 SANOFI PASTEUR INC. $5,197.50 09/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,881.95 09/26/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140531
Principal investigator 1 Mylan Inc. $167.00 09/26/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038724475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50,985.55 09/25/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140587
Principal investigator 1 PFIZER INC. $1,689.60 09/23/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1046239673
Principal investigator 1 PFIZER INC. $5,184.00 09/22/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046242881
Principal investigator 1 BioNTech SE $6,540.75 09/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060314715
Principal investigator 1 BioNTech SE $29,320.00 09/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060314759
Principal investigator 1 Novavax Inc $3,158.94 09/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055266519
Principal investigator 1 Boehringer Ingelheim International GmbH $14,425.00 09/20/2023 Non-covered Recipient Entity
Research Centers Of America
MRD PoCP study in NFLD 12 wks No dispute reported 06/30/2026 1007648615
Principal investigator 1 PFIZER INC. $350.00 09/20/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046257421
Principal investigator 1 SANOFI PASTEUR INC. $6,517.00 09/20/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,334.25 09/15/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140524
Principal investigator 1 SANOFI PASTEUR INC. $8,118.00 09/15/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879689
Principal investigator 1 PFIZER INC. $25,142.64 09/14/2023 Non-covered Recipient Entity
Research Centers of America LLC
A 2 WEEK METHODOLOGY STUDY TO EVALUATE MUSCLE BIOMARKER PERFORMANCE AND MUSCLE BIOPSY PROCEDURE IN HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1046212315
Principal investigator 1 SANOFI PASTEUR INC. $495.00 09/14/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879597
Principal investigator 1 SANOFI PASTEUR INC. $800.00 09/14/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879609
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 09/14/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879633
Principal investigator 1 SANOFI PASTEUR INC. $15,070.00 09/14/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17,825.00 09/13/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,500.00 09/13/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $24,766.00 09/13/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,768.00 09/13/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140579
Principal investigator 1 ModernaTX, Inc. $28.25 09/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1042219161
Principal investigator 1 BioNTech SE $11,755.30 09/12/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060314713
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637665
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637685
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637695
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637705
Principal investigator 1 ModernaTX, Inc. $43.20 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041637725
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637753
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637763
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637841
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637852
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637883
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637893
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637903
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637913
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637923
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637975
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637987
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637997
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638007
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638039
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638049
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638059
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638071
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638101
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638111
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638121
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638173
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638183
Principal investigator 1 ModernaTX, Inc. $43.20 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638193
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638205
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638219
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638267
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638461
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638471
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638482
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638493
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638503
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638513
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638523
Principal investigator 1 ModernaTX, Inc. $43.20 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638533
Principal investigator 1 ModernaTX, Inc. $2,821.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041638543
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638553
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638562
Principal investigator 1 ModernaTX, Inc. $45.90 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638571
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638585
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638595
Principal investigator 1 ModernaTX, Inc. $130.00 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1041638605
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638615
Principal investigator 1 ModernaTX, Inc. $1,147.50 09/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041638625
Principal investigator 1 ModernaTX, Inc. $375.00 09/11/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060501
Principal investigator 1 SANOFI PASTEUR INC. $36,732.22 09/11/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879705
Principal investigator 1 ModernaTX, Inc. $811.89 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041637677
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041637715
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041637933
Principal investigator 1 ModernaTX, Inc. $710.64 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041637943
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638017
Principal investigator 1 ModernaTX, Inc. $710.64 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638029
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638081
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638227
Principal investigator 1 ModernaTX, Inc. $811.89 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638235
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638307
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638347
Principal investigator 1 ModernaTX, Inc. $2,012.85 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041638355
Principal investigator 1 Novavax Inc $526.49 09/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055266517
Principal investigator 1 BioNTech SE $6,109.45 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060314711
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637733
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637743
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637771
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637781
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637791
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637801
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637811
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637821
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637831
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637863
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637873
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637953
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041637963
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638091
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638131
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638143
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638153
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638163
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638247
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638257
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638277
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638287
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638297
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638317
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638327
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638337
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638367
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638379
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638389
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638397
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638407
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638417
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638427
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638439
Principal investigator 1 ModernaTX, Inc. $672.03 09/06/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041638451
Principal investigator 1 ModernaTX, Inc. $9,786.57 09/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220839
Principal investigator 1 SANOFI PASTEUR INC. $1,340.00 09/05/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879853
Principal investigator 1 PFIZER INC. $33,055.36 09/02/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1046240495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,371.05 09/01/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140517
Principal investigator 1 BioNTech SE $1,066.85 09/01/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060314153
Principal investigator 1 PFIZER INC. $3,535.00 09/01/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1046248439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140654
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140673
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140794
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140825
Principal investigator 1 ModernaTX, Inc. $283.89 08/31/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1042219159
Principal investigator 1 PFIZER INC. $164.92 08/30/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046090633
Principal investigator 1 ModernaTX, Inc. $26.55 08/29/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1042219133
Principal investigator 1 ModernaTX, Inc. $26.55 08/29/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1042219135
Principal investigator 1 SANOFI PASTEUR INC. $57,143.72 08/28/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879513
Principal investigator 1 PFIZER INC. $20,128.00 08/24/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1046230337
Principal investigator 1 ModernaTX, Inc. $130.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041637445
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637455
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637465
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637475
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637485
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637495
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637505
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637515
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637657
Principal investigator 1 ModernaTX, Inc. $6,088.26 08/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220855
Principal investigator 1 ModernaTX, Inc. $3,761.10 08/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220857
Principal investigator 1 PFIZER INC. $3,035.06 08/23/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1045921505
Principal investigator 1 SANOFI PASTEUR INC. $800.00 08/23/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879805
Principal investigator 1 ModernaTX, Inc. $53.10 08/22/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1042219137
Principal investigator 1 SANOFI PASTEUR INC. $23,085.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879729
Principal investigator 1 SANOFI PASTEUR INC. $35,400.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879741
Principal investigator 1 SANOFI PASTEUR INC. $400.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879765
Principal investigator 1 SANOFI PASTEUR INC. $600.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879791
Principal investigator 1 SANOFI PASTEUR INC. $800.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879817
Principal investigator 1 SANOFI PASTEUR INC. $800.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879829
Principal investigator 1 SANOFI PASTEUR INC. $800.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879841
Principal investigator 1 SANOFI PASTEUR INC. $1,645.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879865
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 08/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879879
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631343
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631353
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631363
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631373
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631383
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631395
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631407
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631419
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631429
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631439
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631449
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631459
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631469
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631479
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631489
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631499
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631509
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631517
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631529
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631539
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631549
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631559
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631571
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631581
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631589
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631599
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631611
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631621
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631631
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631641
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631651
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631661
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631671
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631683
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631693
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631701
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631713
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631723
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631733
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631743
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631753
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631763
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631773
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631783
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631793
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631803
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631813
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631823
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631833
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631843
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631853
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631863
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631873
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631883
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631893
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631903
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631911
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631923
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631933
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631945
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631953
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631963
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631971
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631979
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631987
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631997
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632007
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632017
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632027
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632037
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632047
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632057
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632069
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632075
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632087
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632099
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632109
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632119
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632129
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632139
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632149
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632159
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632349
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632359
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632369
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632379
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632389
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632399
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632409
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632419
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632429
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632439
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632449
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632459
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041632469
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041632479
Principal investigator 1 ModernaTX, Inc. $101.25 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041632489
Principal investigator 1 ModernaTX, Inc. $101.25 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041632499
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632509
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632519
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632529
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632539
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632549
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632559
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632569
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632579
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632589
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632599
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632609
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632617
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632627
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632637
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632647
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632657
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632667
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632677
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632687
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632697
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632707
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632717
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632727
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632739
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632747
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632755
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632765
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632775
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632785
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632795
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632805
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632817
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632827
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632837
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632847
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632856
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632867
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632877
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632889
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632899
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632907
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632916
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632927
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632935
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632945
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632955
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632969
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632977
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632987
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632999
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633008
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633019
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633029
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633041
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633053
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633063
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633075
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633082
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633091
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633101
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633111
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633121
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633131
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633141
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633151
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633161
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633173
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633183
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633191
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633205
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633215
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633225
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633235
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633245
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633257
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633267
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633277
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633287
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633297
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633307
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633317
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633329
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633339
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633347
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633357
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633367
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633379
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633389
Principal investigator 1 ModernaTX, Inc. $27.68 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041633399
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041633407
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633417
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633427
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633437
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633447
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633457
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633467
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633477
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633487
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633497
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633507
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633517
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633527
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633537
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633547
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633557
Principal investigator 1 ModernaTX, Inc. $101.25 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041633565
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041633575
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633585
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633597
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633607
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633617
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633629
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633637
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633647
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633657
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633667
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633679
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633689
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633699
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633709
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633719
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633729
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633739
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633747
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633757
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633767
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633775
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633787
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041633797
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633807
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633817
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633827
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633837
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633847
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633857
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633867
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633877
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633887
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633899
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633909
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633919
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633929
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633939
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633949
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633959
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633969
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633979
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041633989
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634003
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634013
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634023
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634033
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634043
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634053
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634063
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634073
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634083
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634093
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634103
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634113
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634123
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634137
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634147
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634157
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634167
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634179
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634189
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634199
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634209
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634219
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634229
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634239
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634249
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634257
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634269
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634279
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634289
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634301
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634311
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634321
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634331
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634339
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634349
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634361
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634371
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634381
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634391
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634403
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634413
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634423
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634433
Principal investigator 1 ModernaTX, Inc. $400.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634443
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041634453
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041634465
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634475
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634485
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634493
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634507
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634519
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634529
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634539
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634547
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634557
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634567
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634577
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634587
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634597
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634607
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634617
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634627
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634637
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634645
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634653
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634665
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634673
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634685
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634695
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634703
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634713
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634723
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634733
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634745
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634755
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634765
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634775
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634785
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634795
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634805
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634817
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634829
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634839
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634849
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634859
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634869
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634879
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634889
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634901
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634913
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634921
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634933
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634943
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041634953
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041634963
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634973
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634983
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041634993
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635001
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635013
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635022
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635031
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635045
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635057
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635067
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635077
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635087
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635097
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635107
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635117
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635127
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635137
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635147
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635157
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635167
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635177
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635187
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635197
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635207
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635217
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635227
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635237
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635247
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635257
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635267
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635281
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635289
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635301
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635309
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635319
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635329
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635339
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635351
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635359
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635367
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635379
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635391
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635401
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635411
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041635421
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041635431
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635441
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635451
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635461
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635471
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635481
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635491
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635501
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635511
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635523
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635533
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635543
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635553
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635563
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635573
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635583
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635595
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635607
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635617
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635629
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041635639
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635651
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635661
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635671
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635681
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635691
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635701
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635709
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635723
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635731
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635741
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635751
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635761
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635773
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635785
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635795
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635801
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635811
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635823
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635835
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635845
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635855
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635864
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635875
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635881
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635893
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635905
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635915
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635925
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635935
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635945
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635957
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635967
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635977
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635987
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041635997
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636007
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636017
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636029
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636040
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636049
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636059
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636071
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636081
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636091
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636101
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636111
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636123
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636131
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636141
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636151
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636161
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636171
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636183
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636193
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636203
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636211
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636221
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636231
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636241
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636253
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636261
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636271
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636281
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636295
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636305
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636315
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636325
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636335
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636345
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636357
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636367
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636377
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636389
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636399
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636411
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636421
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636431
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636441
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636451
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636461
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636471
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636481
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636491
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636501
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636511
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636521
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636533
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636543
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636553
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636563
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636573
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636583
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636593
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636603
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636613
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636623
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636633
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636643
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636653
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636663
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636673
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636683
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041636695
Principal investigator 1 ModernaTX, Inc. $101.25 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041636705
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041636715
Principal investigator 1 ModernaTX, Inc. $101.25 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041636725
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636735
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636747
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636757
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636767
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636777
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636787
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636795
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636805
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636819
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636829
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636839
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636849
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636859
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636871
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636880
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636889
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636899
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636909
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636919
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636931
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636939
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636953
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636963
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636973
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636983
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041636993
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637003
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637013
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637023
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637033
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637043
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637053
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637063
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637073
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637087
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637097
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637105
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637115
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637125
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637135
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637147
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637157
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637167
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637179
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637189
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637199
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637207
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637217
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637225
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637233
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637243
Principal investigator 1 ModernaTX, Inc. $101.25 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637255
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637263
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637275
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637285
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637295
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637305
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637315
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637327
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637339
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637349
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637361
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637371
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637381
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637393
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637405
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637415
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637425
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637435
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637525
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637535
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637545
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637555
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637565
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637577
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637587
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637597
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637607
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637617
Principal investigator 1 ModernaTX, Inc. $10.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041637627
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637637
Principal investigator 1 ModernaTX, Inc. $68.85 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041637647
Principal investigator 1 Novavax Inc $4,300.00 08/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262617
Principal investigator 1 SANOFI PASTEUR INC. $2,750.00 08/16/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879463
Principal investigator 1 SANOFI PASTEUR INC. $3,400.00 08/16/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879501
Principal investigator 1 SANOFI PASTEUR INC. $1,250.00 08/16/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879667
Principal investigator 1 SANOFI PASTEUR INC. $400.00 08/16/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879777
Principal investigator 1 SANOFI PASTEUR INC. $35,082.60 08/15/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879489
Principal investigator 1 Novavax Inc $13,000.00 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055259617
Principal investigator 1 Novavax Inc $3,158.94 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055259619
Principal investigator 1 Novavax Inc $526.49 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055262615
Principal investigator 1 Novavax Inc $5,214.51 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055264527
Principal investigator 1 Novavax Inc $3,158.94 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055264529
Principal investigator 1 Novavax Inc $1,024.56 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055265531
Principal investigator 1 Novavax Inc $3,158.94 08/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1055266515
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628305
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628315
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628325
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628335
Principal investigator 1 ModernaTX, Inc. $303.75 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628345
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628355
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628365
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628375
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628385
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628395
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628405
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628415
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628427
Principal investigator 1 ModernaTX, Inc. $2,695.95 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628439
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628447
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628459
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628469
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628479
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628489
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628499
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628509
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628519
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628529
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628539
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628549
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628561
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628571
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628581
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628591
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628601
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628611
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628621
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628631
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628641
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628651
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628661
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628671
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628681
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628691
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628701
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628711
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628721
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628731
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628743
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628751
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628763
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628773
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628783
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628793
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628803
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628813
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628824
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628833
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628844
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628855
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628867
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628877
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628887
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628897
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628907
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628917
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628927
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628937
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628949
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628957
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628967
Principal investigator 1 ModernaTX, Inc. $2,695.95 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628977
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628989
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041628999
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629009
Principal investigator 1 ModernaTX, Inc. $2,695.95 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629019
Principal investigator 1 ModernaTX, Inc. $2,695.95 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629029
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629039
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629051
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629063
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629071
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629081
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629091
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629103
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041629111
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629121
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629132
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629143
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629153
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629163
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629177
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629187
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629197
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629207
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629217
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629225
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629307
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629317
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629325
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629335
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629345
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041629355
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041629365
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041629375
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629387
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629395
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629405
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629413
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629425
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629435
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629447
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629457
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629467
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629477
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629487
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629499
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629509
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629519
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629529
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629541
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041629551
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629561
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629571
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629583
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629593
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629603
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629613
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629621
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629631
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629641
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629651
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629661
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629673
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629681
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629693
Principal investigator 1 ModernaTX, Inc. $2,695.95 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629701
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629713
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629725
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629735
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629745
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629755
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629765
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629777
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041629785
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629795
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629805
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629815
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629829
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629839
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629849
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629859
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629869
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629879
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629889
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629899
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629909
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629919
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629931
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629941
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629951
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629961
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629971
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629983
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041629993
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630005
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630015
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630025
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630035
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630045
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630055
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630065
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630077
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630087
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630097
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630107
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630117
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630127
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041630137
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630147
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630157
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630167
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630179
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630189
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630199
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041630209
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630219
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630229
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630239
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630249
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630259
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630269
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630279
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630289
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630299
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630311
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630321
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630331
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630341
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630351
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630361
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630373
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630383
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630393
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630403
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630413
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041630423
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630433
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630443
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630451
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630461
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630471
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630481
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630491
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630501
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630511
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630521
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630531
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630541
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630551
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630561
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630571
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630581
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630589
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630599
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630609
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630621
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630631
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630639
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630651
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630659
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630671
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630681
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630691
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630701
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630711
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630721
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630731
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630741
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630751
Principal investigator 1 ModernaTX, Inc. $1,159.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630761
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630771
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630781
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630791
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630801
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630811
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630825
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630835
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630845
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630855
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630865
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041630875
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041630885
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630895
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630905
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630915
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630925
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630935
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630945
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630955
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630965
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630975
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630985
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041630995
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631005
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631015
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631025
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631033
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631045
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631055
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631065
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631075
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631085
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631095
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631105
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631115
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631125
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631135
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631145
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631155
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631165
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631175
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631185
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631195
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631203
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631217
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631227
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631237
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631247
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631257
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631267
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631277
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631289
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631299
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631311
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631321
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041631331
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632169
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632179
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632189
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632199
Principal investigator 1 ModernaTX, Inc. $649.17 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1041632209
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632219
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632229
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632239
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632249
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632259
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632269
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632279
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632289
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632297
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632307
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632317
Principal investigator 1 ModernaTX, Inc. $646.65 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632327
Principal investigator 1 ModernaTX, Inc. $10.00 08/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041632337
Principal investigator 1 PFIZER INC. $10,536.68 08/09/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1046256197
Principal investigator 1 SANOFI PASTEUR INC. $211,572.00 08/09/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $42,430.80 08/04/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140555
Principal investigator 1 ModernaTX, Inc. $35,522.88 08/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,352.05 08/02/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140511
Principal investigator 1 PFIZER INC. $1,049.64 08/02/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045932247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140271
Principal investigator 1 SANOFI PASTEUR INC. $76,043.97 07/31/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879621
Principal investigator 1 ModernaTX, Inc. $12,076.97 07/28/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220807
Principal investigator 1 ModernaTX, Inc. $9,055.73 07/28/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220851
Principal investigator 1 SANOFI PASTEUR INC. $36,774.27 07/28/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879753
Principal investigator 1 SANOFI PASTEUR INC. $1,560.06 07/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879451
Principal investigator 1 BioNTech SE $3,200.55 07/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060316565
Principal investigator 1 Boehringer Ingelheim International GmbH $8,662.48 07/26/2023 Non-covered Recipient Entity
Research Centers Of America
MRD PoCP study in NFLD 12 wks No dispute reported 06/30/2026 1007648623
Principal investigator 1 PFIZER INC. $400.00 07/26/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1046023973
Principal investigator 1 PFIZER INC. $2,393.60 07/26/2023 Non-covered Recipient Entity
Research Centers of America LLC
A 2 WEEK METHODOLOGY STUDY TO EVALUATE MUSCLE BIOMARKER PERFORMANCE AND MUSCLE BIOPSY PROCEDURE IN HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1046238351
Principal investigator 1 PFIZER INC. $10,475.04 07/26/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046249293
Principal investigator 1 PFIZER INC. $1,049.64 07/26/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046321077
Principal investigator 1 PFIZER INC. $44,290.82 07/20/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1046325271
Principal investigator 1 PFIZER INC. $18,787.56 07/19/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045897775
Principal investigator 1 BioNTech SE $7,467.95 07/18/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060316621
Principal investigator 1 PFIZER INC. $85,637.11 07/18/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046025373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $72,485.95 07/17/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140593
Principal investigator 1 PFIZER INC. $1,248.63 07/14/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1046160955
Principal investigator 1 BioNTech SE $1,066.85 07/11/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060316577
Principal investigator 1 PFIZER INC. $154,904.25 07/11/2023 Non-covered Recipient Entity
Research Centers of America LLC
A 2 WEEK METHODOLOGY STUDY TO EVALUATE MUSCLE BIOMARKER PERFORMANCE AND MUSCLE BIOPSY PROCEDURE IN HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1046099059
Principal investigator 1 PFIZER INC. $19,167.63 07/08/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046337891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,255.90 07/07/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140537
Principal investigator 1 BioNTech SE $4,398.00 07/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060316583
Principal investigator 1 BioNTech SE $540.00 07/07/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060316609
Principal investigator 1 ModernaTX, Inc. $47,149.58 07/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220849
Principal investigator 1 BioNTech SE $5,334.25 07/04/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060316571
Principal investigator 1 SANOFI PASTEUR INC. $2,900.00 07/04/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879479
Principal investigator 1 SANOFI PASTEUR INC. $3,900.00 07/04/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879525
Principal investigator 1 SANOFI PASTEUR INC. $445.50 07/04/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027287
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027299
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027311
Principal investigator 1 Mylan Inc. $83.50 06/29/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038724481
Principal investigator 1 PFIZER INC. $17,687.67 06/28/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1045987071
Principal investigator 1 SANOFI PASTEUR INC. $128,613.84 06/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55,558.85 06/26/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,000.00 06/26/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 06/26/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/26/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028135
Principal investigator 1 PFIZER INC. $587,472.00 06/24/2023 Non-covered Recipient Entity
Research Centers of America LLC
A 2 WEEK METHODOLOGY STUDY TO EVALUATE MUSCLE BIOMARKER PERFORMANCE AND MUSCLE BIOPSY PROCEDURE IN HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1046311407
Principal investigator 1 PFIZER INC. $55,149.50 06/23/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1045971399
Principal investigator 1 ModernaTX, Inc. $106.25 06/22/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041629247
Principal investigator 1 PFIZER INC. $23,350.00 06/22/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1046025359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,826.55 06/21/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028105
Principal investigator 1 ModernaTX, Inc. $26.55 06/21/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1041629237
Principal investigator 1 BioNTech SE $49,844.00 06/16/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317381
Principal investigator 1 ModernaTX, Inc. $4,217.52 06/14/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1042220809
Principal investigator 1 SANOFI PASTEUR INC. $287,453.30 06/14/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879415
Principal investigator 1 BioNTech SE $1,066.85 06/13/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317365
Principal investigator 1 ModernaTX, Inc. $81.30 06/13/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042121455
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220473
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220475
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220477
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220479
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220481
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220483
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220485
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220487
Principal investigator 1 ModernaTX, Inc. $811.89 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220489
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220491
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220493
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220495
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220497
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220499
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220501
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220503
Principal investigator 1 ModernaTX, Inc. $811.89 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220505
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220565
Principal investigator 1 ModernaTX, Inc. $811.89 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220567
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220569
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220571
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220573
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220575
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220577
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220579
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220581
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220583
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220585
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220587
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220589
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220591
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220593
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220595
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220597
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220599
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220601
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220603
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220605
Principal investigator 1 ModernaTX, Inc. $811.89 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220607
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220609
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220611
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220613
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220615
Principal investigator 1 ModernaTX, Inc. $811.89 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220617
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220619
Principal investigator 1 ModernaTX, Inc. $4,770.33 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220621
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220623
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220625
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220627
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220629
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220631
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220633
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220635
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220637
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220639
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220641
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220643
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220645
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042220647
Principal investigator 1 SANOFI PASTEUR INC. $1,713.30 06/12/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879283
Principal investigator 1 SANOFI PASTEUR INC. $2,724.02 06/12/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879403
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220507
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220509
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220511
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220513
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220515
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220517
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220519
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220521
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220523
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220525
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220527
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220529
Principal investigator 1 ModernaTX, Inc. $1,439.19 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220531
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220533
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220535
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220537
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220539
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220541
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220543
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220545
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220547
Principal investigator 1 ModernaTX, Inc. $672.03 06/09/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220549
Principal investigator 1 SANOFI PASTEUR INC. $9,084.00 06/09/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879377
Principal investigator 1 PFIZER INC. $82.46 06/07/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046315497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $425.00 06/05/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028037
Principal investigator 1 PFIZER INC. $12,250.00 06/03/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1046328851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $250.00 06/02/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $24,712.35 06/02/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70,938.40 06/02/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028097
Principal investigator 1 ModernaTX, Inc. $16,610.94 06/02/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220805
Principal investigator 1 SANOFI PASTEUR INC. $207,155.06 06/02/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879367
Principal investigator 1 ModernaTX, Inc. $8,000.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220551
Principal investigator 1 ModernaTX, Inc. $500.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220553
Principal investigator 1 ModernaTX, Inc. $500.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220555
Principal investigator 1 ModernaTX, Inc. $500.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220557
Principal investigator 1 ModernaTX, Inc. $1,250.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220559
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220561
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042220563
Principal investigator 1 ModernaTX, Inc. $9,408.10 06/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1042220811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027249
Principal investigator 1 PFIZER INC. $3,025.75 05/31/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046091295
Principal investigator 1 ModernaTX, Inc. $2,250.00 05/26/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220751
Principal investigator 1 ModernaTX, Inc. $9,500.00 05/26/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220847
Principal investigator 1 ModernaTX, Inc. $2,000.00 05/26/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220995
Principal investigator 1 BioNTech SE $2,133.70 05/24/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317369
Principal investigator 1 PFIZER INC. $4,236.05 05/24/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046290433
Principal investigator 1 PFIZER INC. $587.00 05/24/2023 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046341445
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 05/24/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879307
Principal investigator 1 ModernaTX, Inc. $766.30 05/22/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220373
Principal investigator 1 ModernaTX, Inc. $1,063.19 05/22/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220387
Principal investigator 1 ModernaTX, Inc. $1,063.19 05/22/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220399
Principal investigator 1 ModernaTX, Inc. $1,063.19 05/22/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220471
Principal investigator 1 ModernaTX, Inc. $81.30 05/19/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042121387
Principal investigator 1 ModernaTX, Inc. $8,981.25 05/19/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1042220779
Principal investigator 1 ModernaTX, Inc. $37,721.25 05/19/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1042220781
Principal investigator 1 ModernaTX, Inc. $7,123.75 05/19/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1042220783
Principal investigator 1 Novavax Inc $977.00 05/19/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260603
Principal investigator 1 SANOFI PASTEUR INC. $269,312.65 05/18/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879343
Principal investigator 1 ModernaTX, Inc. $400.00 05/17/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220397
Principal investigator 1 ModernaTX, Inc. $8,650.00 05/17/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1042220993
Principal investigator 1 BioNTech SE $2,272.40 05/16/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,188.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,233.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $188.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,053.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,026.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $19,449.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,014.00 05/12/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028129
Principal investigator 1 ModernaTX, Inc. $8,650.00 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042219363
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220365
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220367
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220369
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220371
Principal investigator 1 ModernaTX, Inc. $64.80 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220375
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220377
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220379
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220381
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220383
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220385
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220389
Principal investigator 1 ModernaTX, Inc. $810.00 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220391
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220393
Principal investigator 1 ModernaTX, Inc. $985.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220395
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220401
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220403
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220405
Principal investigator 1 ModernaTX, Inc. $810.00 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220407
Principal investigator 1 ModernaTX, Inc. $202.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220409
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220411
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220437
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220439
Principal investigator 1 ModernaTX, Inc. $13.50 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220441
Principal investigator 1 ModernaTX, Inc. $68.85 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220457
Principal investigator 1 ModernaTX, Inc. $154.14 05/10/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220459
Principal investigator 1 BioNTech SE $7,884.05 05/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317363
Principal investigator 1 ModernaTX, Inc. $1,340.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060311
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220203
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220209
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220211
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220213
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220215
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220217
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220219
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220221
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220223
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220225
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220227
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220229
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220231
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220233
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220235
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220237
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220239
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220241
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220243
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220245
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220249
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220251
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220253
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220255
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220257
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220263
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220265
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220267
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220269
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220271
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220273
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220275
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220277
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220281
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220283
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220285
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220287
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220289
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220291
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220297
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220299
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220301
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220303
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220305
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220307
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220309
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220311
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220313
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220315
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220317
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220319
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220321
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220329
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220331
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220333
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220335
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220339
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220341
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220343
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220345
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220347
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220349
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220353
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220355
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220357
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220359
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220413
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220415
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220417
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220419
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220421
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220423
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220425
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220427
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220429
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220431
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220433
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220435
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220443
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220445
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220447
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220449
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220451
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220453
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220455
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220461
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220463
Principal investigator 1 ModernaTX, Inc. $1,063.19 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220465
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220467
Principal investigator 1 ModernaTX, Inc. $672.03 05/08/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220469
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220205
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220207
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220247
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220259
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220261
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220279
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220293
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220295
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220323
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220325
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220327
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220337
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220351
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220361
Principal investigator 1 ModernaTX, Inc. $649.17 05/04/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,988.50 05/03/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $38,836.95 05/03/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028079
Principal investigator 1 BioNTech SE $2,133.70 05/03/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317361
Principal investigator 1 BioNTech SE $27,346.00 05/03/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317379
Principal investigator 1 ModernaTX, Inc. $5,140.07 05/03/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1042220777
Principal investigator 1 ModernaTX, Inc. $51.35 05/02/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042121393
Principal investigator 1 ModernaTX, Inc. $67.28 05/02/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042121401
Principal investigator 1 ModernaTX, Inc. $189.26 05/01/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042121407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997026991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997026997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027097
Principal investigator 1 BioNTech SE $109,180.65 04/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317371
Principal investigator 1 BioNTech SE $79,134.05 04/26/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317373
Principal investigator 1 ModernaTX, Inc. $6,995.00 04/24/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042060135
Principal investigator 1 ModernaTX, Inc. $400.00 04/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220183
Principal investigator 1 ModernaTX, Inc. $6,521.94 04/21/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220775
Principal investigator 1 SANOFI PASTEUR INC. $8,320.00 04/21/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879439
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 04/20/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879269
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 04/20/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879295
Principal investigator 1 SANOFI PASTEUR INC. $9,570.00 04/20/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879319
Principal investigator 1 ModernaTX, Inc. $67.28 04/18/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042121355
Principal investigator 1 SANOFI PASTEUR INC. $1,191,372.76 04/18/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879389
Principal investigator 1 PFIZER INC. $16,460.00 04/12/2023 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046280389
Principal investigator 1 ModernaTX, Inc. $33.64 04/11/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042121369
Principal investigator 1 SANOFI PASTEUR INC. $431,109.83 04/07/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879355
Principal investigator 1 ModernaTX, Inc. $1,516.14 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220175
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220177
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220179
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220181
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220185
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220187
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220189
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220191
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220193
Principal investigator 1 ModernaTX, Inc. $1,516.14 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220195
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220197
Principal investigator 1 ModernaTX, Inc. $649.17 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220199
Principal investigator 1 ModernaTX, Inc. $1,516.14 04/05/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220201
Principal investigator 1 BioNTech SE $750.00 04/04/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317385
Principal investigator 1 BioNTech SE $1,500.00 04/04/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Pre-commercial No dispute reported 06/30/2026 1060317387
Principal investigator 1 ModernaTX, Inc. $204.00 04/04/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042121363
Principal investigator 1 Novavax Inc $977.00 04/04/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055266521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140047
Principal investigator 1 ModernaTX, Inc. $166.50 03/29/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042121319
Principal investigator 1 SANOFI PASTEUR INC. $27,483.08 03/29/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,951.50 03/28/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027975
Principal investigator 1 SANOFI PASTEUR INC. $400.00 03/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878893
Principal investigator 1 SANOFI PASTEUR INC. $1,563.00 03/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878905
Principal investigator 1 SANOFI PASTEUR INC. $280.00 03/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878917
Principal investigator 1 SANOFI PASTEUR INC. $3,034.80 03/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878929
Principal investigator 1 SANOFI PASTEUR INC. $590.00 03/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,110.00 03/22/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $675.00 03/22/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $222.00 03/22/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $69.00 03/22/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997028019
Principal investigator 1 SANOFI PASTEUR INC. $12,112.00 03/22/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879161
Principal investigator 1 ModernaTX, Inc. $33.64 03/21/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042121331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,960.00 03/20/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,512.00 03/20/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,780.00 03/20/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027951
Principal investigator 1 ModernaTX, Inc. $102.00 03/20/2023 Non-covered Recipient Entity
BROWARD RESEARCH GROUP
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042121325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,213.70 03/17/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027939
Principal investigator 1 SANOFI PASTEUR INC. $500.00 03/17/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878983
Principal investigator 1 SANOFI PASTEUR INC. $400.00 03/17/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879009
Principal investigator 1 SANOFI PASTEUR INC. $68,760.90 03/16/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879225
Principal investigator 1 SANOFI PASTEUR INC. $22,295.00 03/16/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879237
Principal investigator 1 Novavax Inc $1,282.00 03/15/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260601
Principal investigator 1 PFIZER INC. $1,017.60 03/15/2023 Non-covered Recipient Entity
Research Centers of America
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046260331
Principal investigator 1 SANOFI PASTEUR INC. $15,419.70 03/15/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035879247
Principal investigator 1 SANOFI PASTEUR INC. $437,334.51 03/15/2023 Non-covered Recipient Entity
Research Centers Of America,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035882337
Principal investigator 1 SANOFI PASTEUR INC. $800.00 03/14/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035878955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28.35 03/13/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139699
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220087
Principal investigator 1 ModernaTX, Inc. $2,263.84 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220089
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220091
Principal investigator 1 ModernaTX, Inc. $2,691.98 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220093
Principal investigator 1 ModernaTX, Inc. $1,704.67 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220095
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220097
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220099
Principal investigator 1 ModernaTX, Inc. $1,250.00 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220101
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220103
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220105
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220107
Principal investigator 1 ModernaTX, Inc. $1,704.67 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220109
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220111
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220113
Principal investigator 1 ModernaTX, Inc. $2,691.98 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220115
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220117
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220119
Principal investigator 1 ModernaTX, Inc. $8,000.00 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220121
Principal investigator 1 ModernaTX, Inc. $672.03 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220123
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220125
Principal investigator 1 ModernaTX, Inc. $672.03 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220127
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220129
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220131
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220133
Principal investigator 1 ModernaTX, Inc. $2,263.84 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220135
Principal investigator 1 ModernaTX, Inc. $672.03 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220137
Principal investigator 1 ModernaTX, Inc. $2,263.84 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220139
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220141
Principal investigator 1 ModernaTX, Inc. $1,704.67 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220143
Principal investigator 1 ModernaTX, Inc. $500.00 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220145
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220147
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220149
Principal investigator 1 ModernaTX, Inc. $672.03 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220151
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220153
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220155
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220157
Principal investigator 1 ModernaTX, Inc. $672.03 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220159
Principal investigator 1 ModernaTX, Inc. $2,691.98 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220161
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220163
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220165
Principal investigator 1 ModernaTX, Inc. $202.50 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220167
Principal investigator 1 ModernaTX, Inc. $672.03 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220169
Principal investigator 1 ModernaTX, Inc. $1,439.19 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220171
Principal investigator 1 ModernaTX, Inc. $896.00 03/13/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042220173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,481.00 03/08/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,734.00 03/08/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,451.00 03/08/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,836.00 03/08/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $270.00 03/08/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 03/08/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028007
Principal investigator 1 Novavax Inc $4,156.00 03/08/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,746.25 03/01/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139841
Principal investigator 1 SANOFI PASTEUR INC. $137,733.75 02/28/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879117
Principal investigator 1 SANOFI PASTEUR INC. $153,851.40 02/28/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879129
Principal investigator 1 SANOFI PASTEUR INC. $6,000.00 02/28/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035879139
Principal investigator 1 SANOFI PASTEUR INC. $10,264.74 02/26/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035878879
Principal investigator 1 SANOFI PASTEUR INC. $15,070.00 02/26/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879093
Principal investigator 1 ModernaTX, Inc. $1,063.19 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219781
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219783
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219785
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219799
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219965
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219967
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219969
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219971
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219973
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219975
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219977
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219979
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219981
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219983
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219985
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219987
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219989
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219991
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219993
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219995
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219997
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219999
Principal investigator 1 ModernaTX, Inc. $748.98 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220001
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220003
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220005
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220007
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220009
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220011
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220013
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220015
Principal investigator 1 ModernaTX, Inc. $748.98 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220017
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220019
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220021
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220023
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220025
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220027
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220029
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220031
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220033
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220035
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220037
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220039
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220041
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220043
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220045
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220047
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220049
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220051
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220053
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220055
Principal investigator 1 ModernaTX, Inc. $748.98 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220057
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220059
Principal investigator 1 ModernaTX, Inc. $748.98 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220061
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220063
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220065
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220067
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220069
Principal investigator 1 ModernaTX, Inc. $595.08 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220071
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220073
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220075
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220077
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220079
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220081
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220083
Principal investigator 1 ModernaTX, Inc. $672.03 02/24/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042220085
Principal investigator 1 PFIZER INC. $339.20 02/23/2023 Non-covered Recipient Entity
Research Centers of America
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046143175
Principal investigator 1 Novavax Inc $66,710.00 02/22/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259623
Principal investigator 1 PFIZER INC. $678.40 02/21/2023 Non-covered Recipient Entity
Research Centers of America
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1046001215
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219765
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219767
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219769
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219771
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219773
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219775
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219777
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219779
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219787
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219789
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219791
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219793
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219795
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219797
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219801
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219803
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219805
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219807
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219809
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219811
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219813
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219815
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219817
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219819
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219821
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219823
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219825
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219827
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219829
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219831
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219833
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219835
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219837
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219839
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219841
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219843
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219845
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219847
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219849
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219851
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219853
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219855
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219857
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219859
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219861
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219863
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219865
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219867
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219869
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219875
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219877
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219895
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219897
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219899
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219901
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219903
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219905
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219907
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219909
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219911
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219923
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219925
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219927
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219929
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219931
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219933
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219935
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219947
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219949
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219951
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219953
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219955
Principal investigator 1 ModernaTX, Inc. $13.50 02/20/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219957
Principal investigator 1 Novavax Inc $1,282.00 02/16/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260597
Principal investigator 1 SANOFI PASTEUR INC. $400.00 02/13/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879069
Principal investigator 1 SANOFI PASTEUR INC. $780.00 02/13/2023 Non-covered Recipient Entity
Research Centers Of America,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035882325
Principal investigator 1 Novavax Inc $5,563.00 02/09/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265535
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219701
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219703
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219705
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219707
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219709
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219711
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219713
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219715
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219717
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219719
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219721
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219723
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219725
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219727
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219729
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219731
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219733
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219735
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219737
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219739
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219741
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219743
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219745
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219747
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219749
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219751
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219753
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219755
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219757
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219759
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219761
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219763
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219871
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219873
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219879
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219881
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219883
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219885
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219887
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219889
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219891
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219893
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219913
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219915
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219917
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219919
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219921
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219937
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219939
Principal investigator 1 ModernaTX, Inc. $1,704.67 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219941
Principal investigator 1 ModernaTX, Inc. $2,263.84 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219943
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219945
Principal investigator 1 ModernaTX, Inc. $2,691.98 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219959
Principal investigator 1 ModernaTX, Inc. $1,516.14 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219961
Principal investigator 1 ModernaTX, Inc. $649.17 02/06/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1042219963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $24,766.00 02/03/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,958.00 02/03/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,915.00 02/03/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 02/03/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027921
Principal investigator 1 SANOFI PASTEUR INC. $48,448.00 02/03/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 02/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 02/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $817.00 02/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 02/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997027995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 02/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $533.00 02/01/2023 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997028013
Principal investigator 1 ModernaTX, Inc. $4,347.96 02/01/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997139141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997139729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 01/31/2023 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997140071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997140083
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219365
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219367
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219369
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219371
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219373
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219375
Principal investigator 1 ModernaTX, Inc. $1,903.14 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219377
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219379
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219381
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219383
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219385
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219387
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219389
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219391
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219393
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219395
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219397
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219399
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219401
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219403
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219405
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219407
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219409
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219411
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219413
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219415
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219417
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219419
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219421
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219423
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219425
Principal investigator 1 ModernaTX, Inc. $2,230.41 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219427
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219429
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219431
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219433
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219435
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219437
Principal investigator 1 ModernaTX, Inc. $519.94 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219439
Principal investigator 1 ModernaTX, Inc. $2,230.41 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219441
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219443
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219445
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219447
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219449
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219451
Principal investigator 1 ModernaTX, Inc. $2,057.51 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219453
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219455
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219457
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219459
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219461
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219463
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219465
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219467
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219469
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219471
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219473
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219475
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219477
Principal investigator 1 ModernaTX, Inc. $2,329.83 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219479
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219481
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219483
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219485
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219487
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219489
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219491
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219493
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219495
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219497
Principal investigator 1 ModernaTX, Inc. $2,057.51 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219499
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219501
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219503
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219505
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219507
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219509
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219511
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219513
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219515
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219517
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219519
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219521
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219523
Principal investigator 1 ModernaTX, Inc. $519.94 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219525
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219527
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219529
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219531
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219535
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219537
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219539
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219541
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219543
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219545
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219547
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219549
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219551
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219553
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219555
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219557
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219559
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219565
Principal investigator 1 ModernaTX, Inc. $2,230.41 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219567
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219569
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219571
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219573
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219575
Principal investigator 1 ModernaTX, Inc. $519.94 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219577
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219579
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219581
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219583
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219585
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219587
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219589
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219591
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219593
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219595
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219597
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219599
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219601
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219603
Principal investigator 1 ModernaTX, Inc. $519.94 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219605
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219607
Principal investigator 1 ModernaTX, Inc. $2,230.41 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219609
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219611
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219613
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219615
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219617
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219619
Principal investigator 1 ModernaTX, Inc. $2,230.41 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219621
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219623
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219625
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219627
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219629
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219631
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219633
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219635
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219637
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219639
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219641
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219643
Principal investigator 1 ModernaTX, Inc. $1,958.71 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219645
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219647
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219649
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219651
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219653
Principal investigator 1 ModernaTX, Inc. $2,329.83 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219655
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219657
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219659
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219661
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219663
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219665
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219667
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219669
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219671
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219673
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219675
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219677
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219679
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219681
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219683
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219685
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219687
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219689
Principal investigator 1 ModernaTX, Inc. $2,057.51 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219691
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219693
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219695
Principal investigator 1 ModernaTX, Inc. $377.91 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219697
Principal investigator 1 ModernaTX, Inc. $2,298.27 01/30/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1042219699
Principal investigator 1 SANOFI PASTEUR INC. $106,938.88 01/27/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035879185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,363.10 01/25/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027273
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219177
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219223
Principal investigator 1 ModernaTX, Inc. $1,250.00 01/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219533
Principal investigator 1 ModernaTX, Inc. $8,000.00 01/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219561
Principal investigator 1 ModernaTX, Inc. $500.00 01/23/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219563
Principal investigator 1 SANOFI PASTEUR INC. $9,582.84 01/20/2023 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1035879173
Principal investigator 1 ModernaTX, Inc. $30,954.15 01/18/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220657
Principal investigator 1 ModernaTX, Inc. $12,747.86 01/18/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
Phase 1/2, randomized, observer-blind to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 and co-administered mRNA-1273 and mRNA-1010 vaccines compared to mRNA-1273 and mRNA-1010 vaccines along in healthy adults 18 to 75 years No dispute reported 06/30/2026 1042220659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,002.10 01/13/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027267
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219165
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219167
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219169
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219171
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219173
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219175
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219179
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219181
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219183
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219185
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219187
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219189
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219191
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219193
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219195
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219197
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219199
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219201
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219203
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219205
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219207
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219209
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219211
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219213
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219215
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219217
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219219
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219221
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219225
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219227
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219229
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219231
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219233
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219235
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219237
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219239
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219241
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219243
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219245
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219247
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219249
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219251
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219253
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219255
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219257
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219259
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219261
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219263
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219265
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219267
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219269
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219271
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219273
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219275
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219277
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219279
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219281
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219283
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219285
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219287
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219289
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219291
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219293
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219295
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219297
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219299
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219301
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219303
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219305
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219307
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219309
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219311
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219313
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219315
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219317
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219319
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219321
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219323
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219325
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219327
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219329
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219331
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219333
Principal investigator 1 ModernaTX, Inc. $748.98 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219335
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219337
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219339
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219341
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219343
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219345
Principal investigator 1 ModernaTX, Inc. $3,490.33 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219347
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219349
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219351
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219353
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219355
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219357
Principal investigator 1 ModernaTX, Inc. $672.03 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219359
Principal investigator 1 ModernaTX, Inc. $15.39 01/12/2023 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042219361
Principal investigator 1 Novavax Inc $6,410.00 01/10/2023 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,757.50 01/04/2023 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997027261